Rocilinostat (ACY-1215): HDAC6 Inhibition in Myeloma Research

Executive Summary: Rocilinostat (ACY-1215) is a highly selective inhibitor of histone deacetylase 6 (HDAC6), exhibiting an IC50 of 5 nM in biochemical assays. Its selectivity enables targeted disruption of cancer cell survival pathways by increasing acetylation of α-tubulin. In multiple myeloma (MM) models, Rocilinostat enhances apoptosis and impedes tumor growth, particularly when used in combination with proteasome inhibitors. The compound is DMSO-soluble and requires cold-chain shipping for stability, as noted by APExBIO. Rocilinostat's research applications are supported by extensive preclinical evidence and validated protocols.

Biological Rationale

Histone deacetylases (HDACs) are enzymes that remove acetyl groups from lysine residues on histones and non-histone proteins, influencing chromatin structure and gene expression. HDAC6 is unique among HDAC family members for its cytoplasmic localization and its role in deacetylating α-tubulin, Hsp90, and cortactin (product information). Overexpression of HDAC6 has been implicated in tumorigenesis, cancer cell survival, cell cycle progression, and metastasis, especially in hematological malignancies such as multiple myeloma (see SulisobenzoneRx for comparison). Inhibiting HDAC6 disrupts these oncogenic processes, making it an attractive target for cancer therapy.

Mechanism of Action of Rocilinostat (ACY-1215)

Rocilinostat (ACY-1215) selectively inhibits HDAC6 with an IC50 of 5 nM, showing minimal activity against other HDAC isoforms (HDAC4, 5, 7, 9, 11) and sirtuins 1 and 2, and only slight inhibition of HDAC8 (product page). The compound increases the acetylation of α-tubulin, disrupting microtubule dynamics necessary for cancer cell motility and division. This leads to impaired cell cycle progression, reduced viability, and enhanced apoptosis in MM cells, particularly when combined with proteasome inhibitors such as bortezomib or carfilzomib (see NortriptylineLabs for protocol advice). Oral administration in mouse models has demonstrated reduced tumor burden and prolonged survival without significant toxicity.

Evidence & Benchmarks

• Rocilinostat demonstrates HDAC6 inhibition with an IC50 of 5 nM in cell-free biochemical assays (APExBIO datasheet).
• It displays >1,000-fold selectivity for HDAC6 over class I HDACs and sirtuins (product information).
• In multiple myeloma cell lines, Rocilinostat decreases cell viability and enhances apoptosis, especially in combination with bortezomib or carfilzomib (SulisobenzoneRx article).
• Oral dosing of Rocilinostat in MM xenograft mouse models delays tumor growth and increases overall survival, with no significant off-target toxicity (APExBIO).
• Rocilinostat is soluble in DMSO (≥21.675 mg/mL), but insoluble in water and ethanol; stability requires -20°C storage and prompt use of solutions (product page).

Applications, Limits & Misconceptions

Rocilinostat (ACY-1215) is intended for research use in preclinical models of multiple myeloma and other cancers with aberrant HDAC6 activity. Its selectivity profile allows targeted investigation of HDAC6's role in cell migration, division, and survival. APExBIO supplies Rocilinostat under SKU A4083 for laboratory research only – it is not approved for diagnostic or medical use. The compound is particularly valuable for studies on HDAC6 inhibition in cancer therapy, enabling elucidation of mechanisms that underlie synergy with proteasome inhibitors (see AldosteroneMed for neural development context).

Common Pitfalls or Misconceptions

• Rocilinostat is not a pan-HDAC inhibitor; it displays minimal activity outside HDAC6 and only slight inhibition of HDAC8.
• The compound is not soluble in water or ethanol, and improper dissolution can impair assay results.
• Solutions should not be stored long-term; fresh preparation is recommended for reproducibility.
• Rocilinostat is for research use only and is not suitable for clinical or diagnostic applications.
• Effects observed in myeloma models may not generalize to solid tumors; confirm context-specific efficacy.

Workflow Integration & Parameters

Protocol Parameters

• Compound preparation: Dissolve Rocilinostat in DMSO to a stock concentration of ≥21.675 mg/mL. Avoid water or ethanol as solvents (product page).
• Storage: Store dry powder and stock solutions at -20°C. Use solutions promptly; avoid long-term storage to maintain activity.
• Cell viability assays: Treat MM cells with 0.1–10 μM Rocilinostat, alone or in combination with 5–20 nM bortezomib; incubate for 24–72 hours depending on assay (protocol guidance).
• Animal dosing: For xenograft models, administer Rocilinostat orally at 50–100 mg/kg/day; monitor tumor volume and survival over 2–4 weeks (see SulisobenzoneRx).
• Synergistic studies: Combine Rocilinostat with proteasome inhibitors to evaluate enhanced anti-myeloma effects, especially in drug-resistant cell lines.
• Handling: Ship and store with blue ice for cold chain integrity; minimize freeze-thaw cycles.

Conclusion & Outlook

Rocilinostat (ACY-1215) represents a validated, highly selective HDAC6 inhibitor suited for preclinical research in multiple myeloma and related cancer models. Its robust selectivity and synergy with proteasome inhibitors provide a mechanistic basis for combination therapies. As a research-only reagent from APExBIO, Rocilinostat enables high-fidelity studies of HDAC6 biology, with clear handling and workflow guidelines. Recent studies further suggest that HDAC6 inhibition may intersect with neural development and ciliary biology, opening new translational research avenues (AldosteroneMed, bridging cancer and neurodevelopment). Ongoing preclinical work will clarify broader therapeutic windows and refine protocols for reproducibility and translational impact.

For a detailed product overview, visit the official Rocilinostat (ACY-1215) page.